Daniel Lee Flynn - 17 Jan 2023 Form 4 Insider Report for Deciphera Pharmaceuticals, Inc.

Role
Chief Scientific Officer
Signature
/s/ Jeffrey M. Held, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
17 Jan 2023
Net transactions value
-$51,043
Form type
4
Filing time
19 Jan 2023, 15:06:03 UTC
Previous filing
21 Jun 2022
Next filing
17 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DCPH Common Stock Sale $51,043 -2,403 -5.2% $21.24 43,695 17 Jan 2023 Direct F1
holding DCPH Common Stock 230,435 17 Jan 2023 By Daniel L. Flynn Revocable Trust
holding DCPH Common Stock 91,020 17 Jan 2023 By Daniel L. Flynn Irrevocable Trust
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was to cover tax liabilities in the vesting of restricted stock.